PURPOSE: To study minimal disseminated disease (MDD) in children with Burkitt's lymphoma (BL) and to determine its impact on prognosis. PATIENTS AND METHODS: We established a simplified long-distance polymerase chain reaction (LD-PCR) assay that can amplify up to 15 to 20 Kb of DNA sequence, making it possible to detect the t(8;14) at the genomic level with sensitivity of 10(-4). We prospectively studied diagnostic biopsies and bone marrow aspirates from 134 patients affected by BL. RESULTS: A specific LD-PCR product was detected in 96 (72%) of 134 BL biopsies. Among 84 patients with t(8;14) positivity on tumor biopsy and bone marrow (BM), 26 (31%) had LD-PCR-positive BM, and 15 (18%) were positive at standard morphologic analysis. Twenty (85%) of 26 MDD-positive patients belonged to the R4 risk group, according to Berlin-Frankfurt-Munster definition. The 3-year progression-free survival was 68% (SE, 10%) in MDD-positive patients in R4 compared with 93% (SE, 5%) in MDD-negative patients in R4 (P = .03). By multivariate analysis (including MDD, sex, lactate dehydrogenase, CNS involvement), only MDD was predictive of higher risk of failure (hazard ratio, 4.7; P = .04). CONCLUSION: MDD identifies a poor-prognosis subgroup among children with high-risk BL. To improve disease control in these patients, a more effective risk-adapted therapy, possibly including anti-CD20 monoclonal antibody, should be considered.
PURPOSE: To study minimal disseminated disease (MDD) in children with Burkitt's lymphoma (BL) and to determine its impact on prognosis. PATIENTS AND METHODS: We established a simplified long-distance polymerase chain reaction (LD-PCR) assay that can amplify up to 15 to 20 Kb of DNA sequence, making it possible to detect the t(8;14) at the genomic level with sensitivity of 10(-4). We prospectively studied diagnostic biopsies and bone marrow aspirates from 134 patients affected by BL. RESULTS: A specific LD-PCR product was detected in 96 (72%) of 134 BL biopsies. Among 84 patients with t(8;14) positivity on tumor biopsy and bone marrow (BM), 26 (31%) had LD-PCR-positive BM, and 15 (18%) were positive at standard morphologic analysis. Twenty (85%) of 26 MDD-positive patients belonged to the R4 risk group, according to Berlin-Frankfurt-Munster definition. The 3-year progression-free survival was 68% (SE, 10%) in MDD-positive patients in R4 compared with 93% (SE, 5%) in MDD-negative patients in R4 (P = .03). By multivariate analysis (including MDD, sex, lactate dehydrogenase, CNS involvement), only MDD was predictive of higher risk of failure (hazard ratio, 4.7; P = .04). CONCLUSION:MDD identifies a poor-prognosis subgroup among children with high-risk BL. To improve disease control in these patients, a more effective risk-adapted therapy, possibly including anti-CD20 monoclonal antibody, should be considered.
Authors: Bruce Shiramizu; Stanton Goldman; Lynette Smith; Melissa Agsalda-Garcia; Paul Galardy; Sherrie L Perkins; J Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Matthew J Barth; Lara Mussolin; Mitchell S Cairo Journal: Br J Haematol Date: 2015-04-08 Impact factor: 6.998
Authors: Angelo Rosolen; Sherrie L Perkins; C Ross Pinkerton; R Paul Guillerman; John T Sandlund; Catherine Patte; Alfred Reiter; Mitchell S Cairo Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Birgit Burkhardt; Mary Taj; Nathalie Garnier; Veronique Minard-Colin; Volkan Hazar; Karin Mellgren; Tomoo Osumi; Alina Fedorova; Natalia Myakova; Jaime Verdu-Amoros; Mara Andres; Edita Kabickova; Andishe Attarbaschi; Alan Kwok Shing Chiang; Eva Bubanska; Svetlana Donska; Lisa Lyngsie Hjalgrim; Jacek Wachowiak; Anna Pieczonka; Anne Uyttebroeck; Jelena Lazic; Jan Loeffen; Jochen Buechner; Felix Niggli; Monika Csoka; Gergely Krivan; Julia Palma; G A Amos Burke; Auke Beishuizen; Kristin Koeppen; Stephanie Mueller; Heidi Herbrueggen; Wilhelm Woessmann; Martin Zimmermann; Adriana Balduzzi; Marta Pillon Journal: Cancers (Basel) Date: 2021-04-25 Impact factor: 6.639